ReviewAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2020
Recent Progress of Potentiating Immune Checkpoint Blockade with External Stimuli-an Industry Perspective.
Review in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Performance evaluation of EuRSC advances · 2025Article
- Computational analysis of LiMgIRSC advances · 2025Article
- Targeted protein delivery based on stimuli-triggered nanomedicine.Exploration (Beijing, China) · 2024Article
- VISTA antibody-loaded FeMaterials today. Bio · 2024Article
- HSPD1 Supports Osteosarcoma Progression through Stabilizing ATP5A1 and thus Activation of AKT/mTOR Signaling.International journal of biological sciences · 2024Article
- SCAPS-1D Modeling of Hydrogenated Lead-Free CsNanomaterials (Basel, Switzerland) · 2023Article
- Biofilm and Cancer: Interactions and Future Directions for Cancer Therapy.International journal of molecular sciences · 2023Review
- Photothermally sensitive gold nanocage augments the antitumor efficiency of immune checkpoint blockade in immune "cold" tumors.Frontiers in immunology · 2023Article
- A pan-cancer analysis reveals the diagnostic and prognostic role of CDCA2 in low-grade glioma.PloS one · 2023Article
- Multiplexed molecular imaging with surface enhanced resonance Raman scattering nanoprobes reveals immunotherapy response in miceNanoscale horizons · 2022Article
- Bioinspired membrane-based nanomodulators for immunotherapy of autoimmune and infectious diseases.Acta pharmaceutica Sinica. B · 2022Review
- Tailor made magnetic nanolights: fabrication to cancer theranostics applications.Nanoscale advances · 2021Review
- Development of theranostic dual-layered Au-liposome for effective tumor targeting and photothermal therapy.Journal of nanobiotechnology · 2021Article
- Impact of beta-2 microglobulin expression on the survival of glioma patients via modulating the tumor immune microenvironment.CNS neuroscience & therapeutics · 2021Article
- Bacteria-Based Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2021Review
- Photodynamic Therapy for the Treatment and Diagnosis ofFrontiers in chemistry · 2021Review
- Tumor immunological phenotype signature-based high-throughput screening for the discovery of combination immunotherapy compounds.Science advances · 2021Article
- Bioengineering of nano metal-organic frameworks for cancer immunotherapy.Nano research · 2021Review
- Immune Cell-Derived Extracellular Vesicles - New Strategies in Cancer Immunotherapy.Frontiers in immunology · 2021Review
- High-Throughput Strategies for the Discovery of Anticancer Drugs by Targeting Transcriptional Reprogramming.Frontiers in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The past decade has seen the materialization of immune checkpoint blockade as an emerging approach to cancer treatment. However, the overall response and patient survival are still modest. Various efforts to study the "cancer immunogram" have highlighted complex biology that necessitates a multipronged approach. This includes increasing the antigenicity of the tumor, strengthening the immune infiltration in the tumor microenvironment, removing the immunosuppressive mechanisms, and reducing immune cell exhaustion. The coordination of these approaches, as well as the ability to enhance them through delivery, is evaluated. Due to their success in multiple preclinical models, external-stimuli-responsive nanoparticles have received tremendous attention. Several studies report success in distantly located tumor regression, metastases, and reoccurrence in preclinical mouse models. However, clinical translation in this space remains low. Herein, the recent advancement in external-stimuli-responsive nanoconstruct-synergized immune checkpoint blockade is summarized, offering an industry perspective on the limitations of current academic innovations and discussing challenges in translation from a technical, manufacturing, and regulatory perspective. These limitations and challenges will need to be addressed to establish external-stimuli-based therapeutic strategies for patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.